Long Grove Pharmaceuticals president Peter J. Karas said by combining its quality pharmaceuticals with Optiscan’s advanced imaging, the company was poised to deliver real innovation and improve outcomes across healthcare.
Optiscan management said the deal showed an increasing number of healthcare companies were interested in working with Optiscan. This type of collaborative agreement could prompt more surgeons to use real-time imaging during surgery, potentially redefining disease treatment to improve patient outcomes.
Optiscan’s proprietary endomicroscope can produce real-time single-cell-resolution 3D images, which are 1000 times sharper than traditional CT or MRI scans. This allows doctors to conduct a precise and immediate optical biopsy during complicated surgeries, thereby reducing the need for repeat procedures.
With the global digital health and surgical tech market booming, Optiscan’s alliance with Long Grove appears to mark a pivotal moment in its US expansion journey. It could well pave the way for a wave of new FDA approvals, commercial partnerships and life-saving clinical applications.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
About The Author
